Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.46 |
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30669226 | 1.00 | CTSK (0.46) | CTSKCTSSPTGESGABRB1GABRB2 | |
| SCHEMBL13584207 | 1.00 | CTSK (0.46) | CTSKCTSSPTGESGABRB1GABRB2 | |
| SCHEMBL13584210 | 1.00 | CTSK (0.46) | CTSKCTSSPTGESGABRB1GABRB2 | |
| SCHEMBL13232075 | 0.85 | CTSK (0.52) | CTSKCTSSGABRB1GABRB2CTSB | |
| SCHEMBL30695638 | 0.85 | CTSK (0.52) | CTSKCTSSGABRB1GABRB2CTSB | |
| SCHEMBL13211537 | 0.85 | CTSK (0.52) | CTSKCTSSGABRB1GABRB2CTSB | |
| SCHEMBL13584844 | 0.82 | PTPN11 (0.43) | PTGESLMNA | |
| SCHEMBL13584847 | 0.82 | PTPN11 (0.43) | PTGESLMNA | |
| SCHEMBL13584754 | 0.81 | CTSK (0.46) | CTSKCTSSPTGESGABRB1GABRB2 | |
| SCHEMBL4542411 | 0.81 | CTSK (0.48) | CTSKCTSSPTGESGABRB1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49735-E1 | Oxazolidinones as modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-28 | — | — | US | disclosed |
| EP-2638022-B1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL MYERS SQUIBB CO (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20120283264-A1 | Oxazolidinones as Modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283264-A1 | Oxazolidinones as Modulators of MGLUR5 | GRM5, GRIK5, GRM1 | CTSK 4566/4885CTSS 4807/4885PTGES 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.